Symbols

EOLS

Evolus·NASDAQ

--(--)

Signals Analysis

Bullish signal 7

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EOLS

Evolus, Inc.

A beauty company that provides medical aesthetic products in the US

Industry

Pharmaceutical

Established Date

Listing Date

02/08/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

334

Fiscal Year Ends

12-31

Website

www.evolus.com

Security Type

Common stock

Office address

520 Newport Center Dr., Suite 1200, Newport Beach, California 92660

Business

Introduction

Evolus, Inc., was incorporated in Delaware in November 2012. The company is a global efficacy beauty company focusing on the self-funded medical beauty market, providing injectable products to licensed beauty practitioners. Its main product, Jeuveau, is a purified botulinum toxin type A for temporarily improving the eyebrow lines, while the company is developing Evolysse, a series of hyaluronic acid gels for injection for facial beauty applications.

Company Financials

EPS

EOLS has released its 2025 Q4 earnings. EPS was reported at 0.04, versus the expected 0.04, meeting expectations. The chart below visualizes how EOLS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EOLS has released its 2025 Q4 earnings report, with revenue of 90.30M, reflecting a YoY change of 14.38%, and net profit of 130.00K, showing a YoY change of 101.91%. The Sankey diagram below clearly presents EOLS's revenue sources and cost distribution.